Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Non-Malignant and Sickle Cell Disease

The Non-Malignant Channel on VJHemOnc is supported by BioMarin Pharmaceutical Inc and Agios Pharmaceuticals. This supporter has no influence over the production of the content.

View overview page
2:27
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
Farrukh Shah • 30 Apr 2024
1:12
Working towards health equity in sickle cell disease: addressing discrimination and bias
Marsha Treadwell • 29 Apr 2024
2:46
Morbidity and mortality data from the UK National Haemoglobinopathy Registry
Farrukh Shah • 30 Apr 2024
3:47
The modeling of HbS dynamics following red cell exchange transfusion to improve patient care
Richard Salisbury • 28 Apr 2024
1:09
Improving the mental health and psychological resilience of patients with SCD
Marsha Treadwell • 29 Apr 2024
2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
0:59
HdxSim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in SCD
Alexandra Power-Hays • 11 Dec 2023
1:28
Use of machine learning to predict outcomes for patients with SCD
Nirmish Shah • 8 Dec 2023
1:43
Approval of exa-cel for SCD
Haydar Frangoul • 14 Dec 2023
0:55
Improving the quality of care for SCD patients transitioning from pediatric to adult
Rabi Hanna • 11 Dec 2023
1:10
Gene therapy for SCD: unanswered questions
Rabi Hanna • 11 Dec 2023
2:16
Correcting the function of mutated hemoglobin with gene therapy for SCD
Akshat Jain • 8 Dec 2023
0:53
Improving quality of life outcomes for patients with SCD
Santosh Saraf • 8 Dec 2023
1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:45
Current landscape of treatment for SCD: an update from ASH 2023
Santosh Saraf • 8 Dec 2023
The Non-Malignant Channel on VJHemOnc is supported by BioMarin Pharmaceutical Inc and Agios Pharmaceuticals. This supporter has no influence over the production of the content.
If you are interested in becoming a supporter of The Non-Malignant Channel, please contact us

The content of VJHemOnc is intended for healthcare professionals